
## Micha T Maeder

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/974592/publications.pdf Version: 2024-02-01



Μιςήλ Τ Μλέρερ

#	Article	lF	CITATIONS
1	Pulmonary hypertension in aortic valve stenosis. Trends in Cardiovascular Medicine, 2022, 32, 73-81.	4.9	20
2	Selexipag and the pulmonary hypertension continuum. European Journal of Heart Failure, 2022, 24, 215-218.	7.1	3
3	Intensification of pharmacological decongestion but not the actual daily loop diuretic dose predicts worse chronic heart failure outcome: insights from TIME-CHF. Clinical Research in Cardiology, 2021, 110, 1221-1233.	3.3	5
4	Corrected QT Interval in Severe Aortic Stenosis: Clinical and Hemodynamic Correlates and Prognostic Impact. American Journal of Medicine, 2021, 134, 267-277.	1.5	4
5	Impact of a volume challenge on haemodynamics and prognosis in patients with severe aortic stenosis. ESC Heart Failure, 2021, 8, 508-517.	3.1	4
6	Editorial Commentary: Biomarkers of cardiovascular risk in obstructive sleep apnea – innovation or illusion?. Trends in Cardiovascular Medicine, 2021, 31, 250-251.	4.9	0
7	Wedge Pressure vs Left Ventricular End-Diastolic Pressure for Pulmonary Hypertension Classification and Prognostication in Severe Aortic Stenosis. CJC Open, 2021, 3, 1428-1437.	1.5	5
8	Pulmonary Hypertension in Patients With Heart Failure With Mid-Range Ejection Fraction. Frontiers in Cardiovascular Medicine, 2021, 8, 694240.	2.4	4
9	Impact of the new pulmonary hypertension definition on <scp>longâ€ŧerm</scp> mortality in patients with severe aortic stenosis undergoing valve replacement. Clinical Cardiology, 2021, 44, 1276-1285.	1.8	11
10	Effect of a strategy of comprehensive vasodilation versus usual care on healthâ€related quality of life among patients with acute heart failure. ESC Heart Failure, 2021, 8, 4218-4227.	3.1	4
11	Hemodynamics Prior to Valve Replacement for Severe Aortic Stenosis and Pulmonary Hypertension during Long-Term Follow-Up. Journal of Clinical Medicine, 2021, 10, 3878.	2.4	1
12	Pulmonary Embolism in a Patient With Hypertrophic Obstructive Cardiomyopathy: Think Outside "the Box― Canadian Journal of Cardiology, 2021, 37, 1275-1277.	1.7	0
13	Invasive Hemodynamic Staging Classification of Cardiac Damage in Patients With Aortic Stenosis Undergoing Valve Replacement. Canadian Journal of Cardiology, 2020, 36, 1667-1674.	1.7	24
14	Relationship between Bâ€ŧype natriuretic peptide and invasive haemodynamics in patients with severe aortic valve stenosis. ESC Heart Failure, 2020, 7, 577-587.	3.1	17
15	Hemodynamic profile of patients with severe aortic valve stenosis and atrial fibrillation versus sinus rhythm. International Journal of Cardiology, 2020, 311, 39-45.	1.7	14
16	Non-invasive assessment prior to invasive coronary angiography in routine clinical practice in Switzerland – Is it according to the guidelines?. PLoS ONE, 2019, 14, e0222137.	2.5	2
17	Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure. JAMA - Journal of the American Medical Association, 2019, 322, 2292.	7.4	85
18	Haemodynamic mechanisms and longâ€ŧerm prognostic impact of pulmonary hypertension in patients with severe aortic stenosis undergoing valve replacement. European Journal of Heart Failure, 2019, 21, 172-181.	7.1	50

#	Article	IF	CITATIONS
19	Use of coronary computed tomography angiography in clinical practice – single centre experience in Switzerland in light of current recommendations based on pretest probability considerations. Swiss Medical Weekly, 2019, 149, w20010.	1.6	1
20	European Society of Cardiology, acute cardiovascular care association, SCAD study group: a position paper on spontaneous coronary artery dissection. European Heart Journal, 2018, 39, 3353-3368.	2.2	421
21	Inverse Association Between Myocardial B-Type Natriuretic Peptide Release and Functional Capacity in Healthy Humans. Heart Lung and Circulation, 2018, 27, 995-1003.	0.4	3
22	Coronary angiography with or without percutaneous coronary intervention in patients with hemophilia—Systematic review. Catheterization and Cardiovascular Interventions, 2018, 92, 1-15.	1.7	21
23	Pulmonary hypertension in stiff left atrial syndrome: pathogenesis and treatment in one. ESC Heart Failure, 2018, 5, 189-192.	3.1	6
24	When the Right Is Not Doing Right: The Role of Strain Imaging in Pulmonary Arterial Hypertension. Canadian Journal of Cardiology, 2018, 34, 962-964.	1.7	2
25	Pulmonary Hypertension in Aortic and Mitral Valve Disease. Frontiers in Cardiovascular Medicine, 2018, 5, 40.	2.4	68
26	Is the clinical presentation of chronic heart failure different in elderly versus younger patients and those with preserved versus reduced ejection fraction?. European Journal of Internal Medicine, 2018, 57, 61-69.	2.2	11
27	Spontaneous Coronary Artery Dissection. Catheterization and Cardiovascular Interventions, 2017, 89, 59-68.	1.7	188
28	Heart failure with midâ€range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure ( <scp>TIMEâ€CHF</scp> ). European Journal of Heart Failure, 2017, 19, 1586-1596.	7.1	108
29	Recurrent left anterior descending artery spasm causing transmural ischaemia treated with stenting. European Heart Journal, 2016, 37, ehv309.	2.2	1
30	A clinical approach to obstructive sleep apnea as a risk factor for cardiovascular disease. Vascular Health and Risk Management, 2016, 12, 85.	2.3	60
31	Biomarkers of cardiovascular stress in obstructive sleep apnea. Clinica Chimica Acta, 2016, 460, 152-163.	1.1	26
32	Kounis syndrome revisited: Systemic mastocytosis and severe coronary artery disease. International Journal of Cardiology, 2016, 214, 510-511.	1.7	5
33	Prognostic Value of the Change in Heart Rate From the Supine to the Upright Position in Patients With Chronic Heart Failure. Journal of the American Heart Association, 2016, 5, .	3.7	3
34	Severely worsening dyspnea after initiation of macitentan therapy for pulmonary arterial hypertension. International Journal of Cardiology, 2016, 202, 244-245.	1.7	5
35	Accuracy of Echocardiographic Cardiac Index Assessment in Subjects with Preserved Left Ventricular Ejection Fraction. Echocardiography, 2015, 32, 1628-1638.	0.9	17
36	Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. European Journal of Heart Failure, 2015, 17, 1006-1014.	7.1	198

#	Article	IF	CITATIONS
37	Impact of worsening renal function related to medication in heart failure. European Journal of Heart Failure, 2015, 17, 159-168.	7.1	37
38	Giant biventricular thrombi in a patient with heart failure and heparin-induced thrombocytopenia. International Journal of Cardiology, 2015, 182, 377-378.	1.7	5
39	Improvement in left ventricular ejection fraction and reverse remodeling in elderly heart failure patients on intense NT-proBNP-guided therapy. International Journal of Cardiology, 2015, 191, 286-293.	1.7	9
40	Differential Prognostic Impact of Resting Heart Rate in Older Compared With Younger Patients With Chronic Heart Failure—Insights From TIME-CHF. Journal of Cardiac Failure, 2015, 21, 347-354.	1.7	7
41	Comprehensive biomarker profiling in patients with obstructive sleep apnea. Clinical Biochemistry, 2015, 48, 340-346.	1.9	42
42	Midregional pro-adrenomedullin and copeptin: exercise kinetics and association with the cardiopulmonary exercise response in comparison to B-type natriuretic peptide. European Journal of Applied Physiology, 2014, 114, 815-824.	2.5	11
43	More on heart rate variability in obstructive sleep apnea: confusion on a higher level or first step to unravel the cardiovascular mystery of the sleep apnea patient?. Sleep and Breathing, 2014, 18, 233-234.	1.7	3
44	Determinants and implications of elevated soluble ST2 levels in heart failure. International Journal of Cardiology, 2014, 176, 1242-1243.	1.7	9
45	Reduced left atrial early strain rate following acute sleep deprivation: chance finding or chance to find out more on the conundrum of sleep and cardiovascular disease?. Sleep and Breathing, 2013, 17, 899-901.	1.7	3
46	Noninvasive Assessment of Pulmonary Vascular Resistance by Doppler Echocardiography. Journal of the American Society of Echocardiography, 2013, 26, 1170-1177.	2.8	141
47	Nâ€ŧerminal pro brain natriuretic peptideâ€guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME HF). European Journal of Heart Failure, 2013, 15, 1148-1156	7.1	62
48	Safety and tolerability of intensified, Nâ€terminal pro brain natriuretic peptideâ€guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIMEâ€CHF. European Journal of Heart Failure, 2013, 15, 910-918.	7.1	21
49	Changes in BNP and QTc for prediction of sudden death in heart failure. Future Cardiology, 2013, 9, 317-320.	1.2	2
50	Research Highlights: Ultrasensitive cardiac troponin and myocardial strain predict cardiotoxicity. Biomarkers in Medicine, 2012, 6, 785-788.	1.4	1
51	Heart rate recovery in obstructive sleep apnea: scientific toy or clinical tool?. Sleep and Breathing, 2012, 16, 593-594.	1.7	3
52	Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy. American Heart Journal, 2012, 163, 407-414.e1.	2.7	71
53	Reply to letter to the editor entitled "Proposed strategy for optimizing aldosterone blockade in heart failure―by Dr Jolobe. American Heart Journal, 2012, 164, e3.	2.7	0
54	Hemodynamic Determinants of the Abnormal Cardiopulmonary Exercise Response in Heart Failure With Preserved Left Ventricular Ejection Fraction. Journal of Cardiac Failure, 2012, 18, 702-710.	1.7	33

#	Article	IF	CITATIONS
55	Accuracy of Doppler Echocardiography to Estimate Key Hemodynamic Variables in Subjects With Normal Left Ventricular Ejection Fraction. Journal of Cardiac Failure, 2011, 17, 405-412.	1.7	30
56	Determinants of absolute and relative exercise-induced changes in B-type natriuretic peptides. International Journal of Cardiology, 2011, 147, 409-415.	1.7	9
57	Transcardiac gradients of B-type natriuretic peptides are increased in human pulmonary arterial hypertension. International Journal of Cardiology, 2011, 151, 117-119.	1.7	4
58	Determinants of Postexercise Heart Rate Recovery in Patients With the Obstructive Sleep Apnea Syndrome. Chest, 2010, 137, 310-317.	0.8	15
59	Copeptin Response to Clinical Maximal Exercise Tests. Clinical Chemistry, 2010, 56, 674-676.	3.2	19
60	Hemodynamic Determinants of Myocardial B-Type Natriuretic Peptide Release. Hypertension, 2010, 56, 682-689.	2.7	64
61	Biomarkers and Peak Oxygen Uptake in Patients with Chronic Lung Disease. Respiration, 2010, 80, 543-552.	2.6	10
62	Response to Does the Wall Stress Alone Stimulate the Natriuretic Peptide System?. Hypertension, 2010, 56, .	2.7	0
63	Predictors of impaired heart rate recovery: a myocardial perfusion SPECT study. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 303-308.	2.8	7
64	Hemodynamic Basis of Exercise Limitation in Patients With Heart Failure and Normal Ejection Fraction. Journal of the American College of Cardiology, 2010, 56, 855-863.	2.8	300
65	Midregional pro-A-type natriuretic peptide for the evaluation of exercise intolerance. International Journal of Cardiology, 2010, 145, 326-328.	1.7	3
66	Natriuretic peptides for the prediction of severely impaired peak VO2 in patients with lung disease. Respiratory Medicine, 2009, 103, 1337-1345.	2.9	9
67	Continuous positive airway pressure improves exercise capacity and heart rate recovery in obstructive sleep apnea. International Journal of Cardiology, 2009, 132, 75-83.	1.7	29
68	Heart Failure With Normal Left Ventricular Ejection Fraction. Journal of the American College of Cardiology, 2009, 53, 905-918.	2.8	241
69	N-terminal pro-B-type natriuretic peptide and functional capacity in patients with obstructive sleep apnea. Sleep and Breathing, 2008, 12, 7-16.	1.7	27
70	Use of B-type natriuretic peptide outside of the emergency department. International Journal of Cardiology, 2008, 127, 5-16.	1.7	35
71	Association between heart rate recovery and severity of obstructive sleep apnea syndrome. Sleep Medicine, 2008, 9, 753-761.	1.6	49
72	Tricuspid Regurgitation Contributes to Renal Dysfunction in Patients With Heart Failure. Journal of Cardiac Failure, 2008, 14, 824-830.	1.7	92

#	Article	IF	CITATIONS
73	Long-term outcomes after intracoronary Beta-irradiation for in-stent restenosis in bare-metal stents. Journal of Invasive Cardiology, 2008, 20, 179-84.	0.4	1
74	B-type natriuretic peptide kinetics and cardiopulmonary exercise testing in heart failure. International Journal of Cardiology, 2007, 120, 391-398.	1.7	12
75	Adenosine-induced severe acute respiratory distress in chronic obstructive pulmonary disease: a myth?. Swiss Medical Weekly, 2007, 137, 212.	1.6	3
76	Bland–White–Garland syndrome and atrial septal defect—. Clinical Research in Cardiology, 2006, 95, 295-300.	3.3	15
77	Impact of a lead glass screen on scatter radiation to eyes and hands in interventional cardiologists. Catheterization and Cardiovascular Interventions, 2006, 67, 18-23.	1.7	81
78	Sepsis-Associated Myocardial Dysfunction. Chest, 2006, 129, 1349-1366.	0.8	267
79	B-type natriuretic peptide in patients with sepsis and preserved left ventricular ejection fraction. European Journal of Heart Failure, 2005, 7, 1164-1167.	7.1	35
80	Impact of the Exercise Mode on Exercise Capacity. Chest, 2005, 128, 2804-2811.	0.8	48
81	Idiopathic spontaneous coronary artery dissection: incidence, diagnosis and treatment. International Journal of Cardiology, 2005, 101, 363-369.	1.7	135
82	Cytologically malignant lymphoid pericardial effusion with benign clinical outcome. Swiss Medical Weekly, 2005, 135, 377-81.	1.6	2
83	Contrast nephropathy: Review focusing on prevention. Journal of the American College of Cardiology, 2004, 44, 1763-1771.	2.8	204
84	Bland-White-Garland Syndrome in a 39-Year-Old Mother. Annals of Thoracic Surgery, 2004, 78, 1451-1453.	1.3	14
85	Elevation of B-type natriuretic peptide levels in acute respiratory distress syndrome. Swiss Medical Weekly, 2003, 133, 515-8.	1.6	28